Nuvation Bio Inc. Class A
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $3.90
- 52-Week Range
- $3.77 – $9.75
- Market Cap
- $1.33B
- P/E (TTM)
- —
- EPS (TTM)
- -0.39
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 5.85
- PEG Ratio
- —
- Return on Equity
- -49.09%
- Return on Assets
- -11.18%
- Gross Margin
- 85.79%
- Operating Margin
- -61.17%
- Profit Margin
- -67.38%
- Current Ratio
- 7.45
- Debt/Equity
- 2.05
- Total Debt
- $468.12M
- Free Cash Flow
- $-76.06M
- Revenue Growth
- 242.60%
- Earnings Growth
- —
- Enterprise Value
- $1.14B
Market Snapshot
About
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company developing precision oncology therapies. The company focuses on cancer treatments targeting specific genetic alterations and tumor biology mechanisms.